Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,645,930
  • Shares Outstanding, K 24,493
  • Annual Sales, $ 20,790 K
  • Annual Income, $ -25,990 K
  • 60-Month Beta 3.01
  • Price/Sales 115.88
  • Price/Cash Flow N/A
  • Price/Book 6.50
Trade ARCT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.92
  • Number of Estimates 7
  • High Estimate -0.65
  • Low Estimate -1.19
  • Prior Year -0.76
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.11 +67.54%
on 12/29/20
103.00 -34.76%
on 12/28/20
-30.93 (-31.52%)
since 12/24/20
3-Month
32.88 +104.38%
on 11/09/20
129.71 -48.19%
on 12/07/20
+14.62 (+27.81%)
since 10/27/20
52-Week
8.51 +689.66%
on 03/13/20
129.71 -48.19%
on 12/07/20
+56.15 (+508.14%)
since 01/27/20

Most Recent Stories

More News
7 Nasdaq ETFs to Play the Index's Winning Momentum

The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.

SSYS : 45.12 (+6.44%)
QQQ : 319.43 (-2.79%)
ARCT : 67.20 (+3.40%)
XNET : 4.72 (+2.39%)
QQEW : 100.81 (-3.04%)
QLD : 119.14 (-5.38%)
ONEQ : 515.68 (-2.48%)
TQQQ : 95.08 (-8.06%)
QQQM : 131.45 (-2.66%)
QQQJ : 31.45 (-2.87%)
Should you invest in Tesla, Arcturus Therapeutics, Boeing, AT&T, or Uber Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, ARCT, BA, T, and UBER.

ARCT : 67.20 (+3.40%)
TSLA : 864.16 (-2.14%)
BA : 194.03 (-3.97%)
T : 29.14 (-2.05%)
UBER : 48.11 (-7.34%)
Nasdaq Hits 13,000 for the First Time: ETFs to Bet On

The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.

SSYS : 45.12 (+6.44%)
QQQ : 319.43 (-2.79%)
ARCT : 67.20 (+3.40%)
XNET : 4.72 (+2.39%)
QQEW : 100.81 (-3.04%)
QLD : 119.14 (-5.38%)
ONEQ : 515.68 (-2.48%)
TQQQ : 95.08 (-8.06%)
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates

The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.

INCY : 93.00 (-6.43%)
MRNA : 155.73 (+2.50%)
BMY : 62.02 (-3.76%)
ARCT : 67.20 (+3.40%)
CALA : 2.97 (-2.94%)
Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant...

ARCT : 67.20 (+3.40%)
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study

Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.

AZN : 52.10 (-4.30%)
PFE : 36.24 (-2.87%)
MRNA : 155.73 (+2.50%)
ARCT : 67.20 (+3.40%)
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

--Anticipate interim Phase 2 data in early 2021; targeting global Phase 3 study start in Q2 2021 which could allow application for emergency use authorization/conditional approval in H2 2021

ARCT : 67.20 (+3.40%)
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis

Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.

VRTX : 225.25 (-5.21%)
ARCT : 67.20 (+3.40%)
AZRX : 1.6400 (-17.59%)
ARPO : 1.2100 (-6.92%)
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More

The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).

REGN : 515.56 (-5.25%)
PFE : 36.24 (-2.87%)
BMY : 62.02 (-3.76%)
NVAX : 131.18 (+3.16%)
ARCT : 67.20 (+3.40%)
MYOV : 22.88 (+1.06%)
APRE : 5.38 (-4.61%)
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results

Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.

PFE : 36.24 (-2.87%)
MRNA : 155.73 (+2.50%)
ARCT : 67.20 (+3.40%)
BNTX : 105.97 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 83.18
2nd Resistance Point 77.51
1st Resistance Point 72.35
Last Price 67.20
1st Support Level 61.53
2nd Support Level 55.87
3rd Support Level 50.71

See More

52-Week High 129.71
Fibonacci 61.8% 83.41
Fibonacci 50% 69.11
Last Price 67.20
Fibonacci 38.2% 54.81
52-Week Low 8.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar